Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Irhythm Technologies Inc Stock Research

IRTC

84.96USD-0.01(-0.01%)Market Closed
Watchlist

Market Summary

USD84.96-0.01
Market Closed
-0.01%

IRTC Alerts

  • Losses in recent quarter

IRTC Stock Price

IRTC RSI Chart

IRTC Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-26.15

Price/Sales (Trailing)

5.74

EV/EBITDA

-31.26

Price/Free Cashflow

-51.57

IRTC Price/Sales (Trailing)

IRTC Profitability

Operating Margin

68.74%

EBT Margin

-24.27%

Return on Equity

-47.18%

Return on Assets

-24.82%

Free Cashflow Yield

-1.94%

IRTC Fundamentals

IRTC Revenue

Revenue (TTM)

452.1M

Revenue Y/Y

21.64%

Revenue Q/Q

11.39%

IRTC Earnings

Earnings (TTM)

-99.2M

Earnings Y/Y

22.66%

Earnings Q/Q

52.74%

Price Action

52 Week Range

82.51140.23
(Low)(High)

Last 7 days

-9.1%

Last 30 days

-18.6%

Last 90 days

-15.8%

Trailing 12 Months

-28.7%

IRTC Financial Health

Current Ratio

3.1

IRTC Investor Care

Shares Dilution (1Y)

2.37%

Diluted EPS (TTM)

-3.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for IRTC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-09
Bobzien Brice
sold
-150,909
111
-1,356
chief financial officer
2023-08-03
Day Mark J.
acquired
17,602
36.22
486
chief technology officer
2023-08-02
Patterson Chad
sold
-190,529
100
-1,896
chief commercial officer
2023-07-03
Turakhia Minang
sold
-102,238
103
-988
evp, cmo & cso
2023-07-03
Wilson Daniel G.
sold
-154,185
103
-1,490
evp, corp dev inv rel
2023-06-06
Blackford Quentin S.
acquired
997,644
102
9,755
president and ceo
2023-06-02
Shrishrimal Sumi
sold
-123,598
111
-1,109
evp, chief risk officer
2023-06-01
YOOR BRIAN B
acquired
-
-
2,399
-
2023-06-01
Poul Mojdeh
acquired
-
-
2,399
-
2023-05-31
Bairey Merz Cathleen Noel
back to issuer
-60,387
118
-509
-

1–10 of 50

Which funds bought or sold IRTC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
31.73
203,000
2,097,000
-%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
-60,904
322,349
0.02%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-1,866,810
9,880,560
0.10%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
sold off
-100
-409,299
-
-%
2023-08-22
COMERICA BANK
new
-
76,000
76,000
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-1.75
-811,549
3,861,400
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-27.76
-124,861
193,253
-%
2023-08-17
Orion Portfolio Solutions, LLC
reduced
-43.13
-1,376,020
1,261,860
0.01%
2023-08-16
Nuveen Asset Management, LLC
reduced
-18.61
-4,044,290
8,775,710
-%
2023-08-15
EVENTIDE ASSET MANAGEMENT, LLC
unchanged
-
-4,713,350
24,946,600
0.42%

1–10 of 43

Latest Funds Activity

Are funds buying IRTC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IRTC
No. of Funds

Schedule 13G FIlings of Irhythm Tech

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
sands capital management, llc
9.1%
2,667,428
SC 13G/A
Feb 09, 2023
vanguard group inc
9.55%
2,876,849
SC 13G/A
Jan 31, 2023
blackrock inc.
7.6%
2,288,507
SC 13G/A
Jan 27, 2023
mackenzie financial corp
4.14%
1,246,524
SC 13G/A
Feb 14, 2022
sands capital management, llc
10.34%
3,041,867
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
1.7%
524,505
SC 13G/A
Feb 04, 2022
mackenzie financial corp
5.73%
1,685,430
SC 13G/A
Feb 03, 2022
blackrock inc.
7.1%
2,084,707
SC 13G/A
Jan 24, 2022
jpmorgan chase & co
7.0%
2,083,625
SC 13G
Jul 09, 2021
brown capital management llc
0%
0
SC 13G/A

Recent SEC filings of Irhythm Tech

View All Filings
Date Filed Form Type Document
Aug 18, 2023
3
Insider Trading
Aug 16, 2023
4/A
Insider Trading
Aug 16, 2023
4/A
Insider Trading
Aug 16, 2023
4/A
Insider Trading
Aug 16, 2023
4/A
Insider Trading
Aug 16, 2023
4/A
Insider Trading
Aug 16, 2023
4/A
Insider Trading
Aug 15, 2023
8-K
Current Report
Aug 15, 2023
3
Insider Trading
Aug 10, 2023
4
Insider Trading

Peers (Alternatives to Irhythm Tech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
103.9B
19.5B
-1.64% 35.04%
38.34
5.34
10.36% 30.30%
102.1B
6.7B
-2.29% 54.71%
71.68
15.33
11.75% -0.66%
76.4B
13.4B
4.08% 37.72%
83.77
5.7
8.69% 3.17%
71.3B
19.0B
-6.81% 13.51%
44.09
3.79
0.46% -5.24%
42.8B
5.7B
-7.61% -15.82%
30.79
7.56
5.64% -4.53%
MID-CAP
9.4B
937.8M
-2.31% 34.57%
323.13
10.04
16.30% 250.21%
7.2B
616.6M
-8.54% -23.02%
29.49
11.66
69.52% 343.68%
5.0B
1.1B
-9.61% -15.17%
23.63
4.53
12.63% 50.85%
2.6B
452.1M
-18.56% -28.66%
-26.15
5.74
24.99% 24.09%
1.4B
790.3M
-22.43% -53.70%
-6.08
1.73
3.21% -1604.53%
SMALL-CAP
1.5B
421.8M
-14.76% 54.69%
-9.15
3.62
44.49% -2.43%
953.5M
780.7M
-5.52% -6.22%
-26.49
1.22
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
608.6M
162.9M
-22.30% -62.37%
-11.51
3.74
42.67% 12.82%

Irhythm Tech News

Best Stocks
Macquarie Group Ltd. Reduces Stake in iRhythm Technologies, Inc ....
Best Stocks,
6 days ago

Returns for IRTC

Cumulative Returns on IRTC

-2.2%


5-Year Cumulative Returns

-27.9%


3-Year Cumulative Returns

Risks for IRTC

What is the probability of a big loss on IRTC?

100%


Probability that Irhythm Tech stock will be more than 20% underwater in next one year

82.3%


Probability that Irhythm Tech stock will be more than 30% underwater in next one year.

39.6%


Probability that Irhythm Tech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IRTC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Irhythm Tech was unfortunately bought at previous high price.

Drawdowns

Financials for Irhythm Tech

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue5.1%452,058,000429,979,000410,921,000380,108,000361,665,000340,892,000322,825,000319,830,000306,342,000275,942,000265,166,000245,461,000228,190,000229,753,000214,552,000197,230,000180,998,000163,849,000147,277,000133,678,000120,272,000
Gross Profit5.4%311,534,000295,554,000281,632,000254,208,000239,435,000224,473,000213,567,000220,595,000218,159,000198,270,000194,889,000181,767,000168,943,000172,978,000162,067,000147,854,000135,454,000121,831,000108,482,00097,982,00087,609,000
Operating Expenses2.8%411,694,000400,293,000395,416,000379,493,000366,916,000345,495,000313,510,000297,920,000276,959,000260,240,000238,562,000233,585,000234,264,000228,702,000216,822,000197,974,000176,535,000165,128,000154,173,000141,649,000128,038,000
  S&GA Expenses2.8%359,052,000349,383,000322,198,000307,080,000297,266,000278,184,000274,839,000259,515,000238,471,000218,816,000197,233,000194,592,000190,540,000189,687,000179,523,000162,859,000149,833,000141,612,000133,313,000123,795,000111,480,000
  R&D Expenses3.4%52,642,00050,910,00046,610,00045,805,00043,042,00040,703,00038,671,00038,405,00038,488,00041,424,00041,329,00038,993,00043,724,00039,015,00037,299,00035,115,00026,702,00023,516,00020,860,00017,854,00016,558,000
EBITDA100.0%--87,406,000-98,343,000-111,816,000-115,310,000-110,108,000-89,983,000-68,206,000-49,836,000-53,482,000-35,182,000-43,590,000-58,066,000-49,311,000-49,415,000------
EBITDA Margin100.0%--0.20-0.24-0.29-0.32-0.32-0.28-0.21-0.16-0.19-0.13-0.18-0.25-0.21-0.23------
Interest Expenses11.4%3,409,0003,059,0004,138,0003,373,0003,038,0002,863,0001,169,0001,295,0001,400,0001,474,0001,519,0001,530,0001,555,0001,614,0001,643,0001,793,0002,245,0002,666,0003,115,0003,444,0003,445,000
Earnings Before Taxes5.4%-98,751,000-104,346,000-115,886,000-128,193,000-130,495,000-123,875,000-100,994,000-78,237,000-59,172,000-62,234,000-43,601,000-51,208,000-64,909,000-55,313,000-54,503,000-53,447,000-44,901,000-46,397,000-50,334,000-44,066,666-46,646,000
EBT Margin100.0%--0.24-0.28-0.34-0.36-0.36-0.31-0.24-0.19-0.23-0.16-0.21-0.28-0.24-0.25------
Net Income5.2%-99,240,000-104,655,000-116,155,000-128,448,000-130,728,000-124,191,000-101,361,000-78,521,000-59,467,000-62,544,000-43,830,000-51,479,000-65,095,000-55,383,000-54,568,000-53,538,000-44,972,000-47,551,000-50,378,000-45,257,000-42,054,000
Net Income Margin100.0%--0.24-0.28-0.34-0.36-0.36-0.31-0.25-0.19-0.23-0.17-0.21-0.29-0.24-0.25------
Free Cashflow100.0%--47,561,000-52,842,000-75,995,000-68,962,000-64,224,000-65,820,000-42,696,000-41,724,000-47,592,000-27,310,000-49,441,000-59,815,000-49,223,000-42,320,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets1.8%429422448440436429463480485478512497276283306310205115118118120
  Current Assets-4.6%24225428928628528630632533633637836614715417318592.0092.00104106109
    Cash Equivalents16.6%62.0053.0079.0071.0010195.0012816713913789.0095.0082.0057.0020.0035.0016.0028.0020.0017.0019.00
  Inventory-11.7%14.0016.0015.0014.0014.0012.0010.0010.009.007.005.005.005.004.004.003.003.003.002.002.002.00
  Net PPE9.3%90.0082.0076.0072.0066.0057.0056.0053.0047.0037.0034.0033.0030.0028.0026.0018.0013.0010.009.008.008.00
  Goodwill0%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities2.9%20620020820119118418318417916917016315815817116715968.0065.0055.0053.00
  Current Liabilities9.2%89.0082.0089.0084.0070.0062.0088.0083.0073.0059.0066.0056.0047.0043.0052.0045.0035.0029.0030.0023.0020.00
  Long Term Debt-------10.00---21.00---33.00---35.00--
    LT Debt, Non Current0.0%35.0035.0035.0035.0035.0035.0010.0013.0016.0018.0021.0024.0027.0030.0033.0035.0035.0035.0035.0033.0033.00
Shareholder's Equity0.9%22422224023924524528029630631034233511812513514347.0048.0052.0063.0067.00
  Retained Earnings-3.3%-579-561-522-502-480-456-406-373-349-332-304-295-290-269-260-243-224-214-205-189-179
  Additional Paid-In Capital2.6%804783762742726702686669656642646629408395396386271262258253247
Shares Outstanding0.3%31.0030.0030.0030.0030.0030.0029.0029.0029.0029.0029.0028.0027.0027.0027.0025.0025.0024.0024.0024.0024.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-28.2%-19.08-14.88-23.01-48.63-34.62-34.80-37.75-16.89-23.62-33.23-13.76-26.44-38.24-27.07-21.86-21.38-25.61-33.00-29.09-28.44-27.13
  Share Based Compensation-1.6%61.0062.0058.0054.0053.0048.0055.0057.0062.0061.0042.0035.0025.0022.0026.0024.0021.0018.0016.0014.0013.00
Cashflow From Investing23.5%-30.65-40.09-52.43-71.45-22.43-20.30105115-103-75.27-132-127-10.00-55.74-89.27-72.4716.0039.0034.0019.0024.00
Cashflow From Financing-22.2%10.0013.0027.0024.0019.0013.00-28.58-25.991841892142151141111121116.006.006.006.006.00

IRTC Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue, net$ 124,130,000$ 102,051,000$ 235,566,000$ 194,429,000
Cost of revenue37,905,00031,806,00073,660,00062,425,000
Gross profit86,225,00070,245,000161,906,000132,004,000
Operating expenses:    
Research and development13,677,00011,945,00028,519,00022,487,000
Selling, general and administrative91,420,00081,751,000191,763,000154,909,000
Impairment and restructuring charges00026,608,000
Total operating expenses105,097,00093,696,000220,282,000204,004,000
Loss from operations(18,872,000)(23,451,000)(58,376,000)(72,000,000)
Interest expense(832,000)(482,000)(1,782,000)(2,511,000)
Interest and other income, net1,435,00069,0002,867,00085,000
Loss before income taxes(18,269,000)(23,864,000)(57,291,000)(74,426,000)
Income tax provision213,00033,000300,00080,000
Net loss$ (18,482,000)$ (23,897,000)$ (57,591,000)$ (74,506,000)
Net loss per common share, basic (in USD per share)$ (0.61)$ (0.80)$ (1.89)$ (2.51)
Net loss per common share, diluted (in USD per share)$ (0.61)$ (0.80)$ (1.89)$ (2.51)
Weighted-average shares, basic (in shares)30,50229,84330,40029,720
Weighted-average shares, diluted (in shares)30,50229,84330,40029,720

IRTC Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 61,578$ 78,832
Marketable securities103,161134,312
Accounts receivable, net51,10849,918
Inventory14,47815,155
Prepaid expenses and other current assets11,81610,555
Total current assets242,141288,772
Property and equipment, net89,84575,670
Operating lease right-of-use assets57,91760,666
Goodwill862862
Other assets38,72322,252
Total assets429,488448,222
Current liabilities:  
Accounts payable7,1507,517
Accrued liabilities64,46965,497
Deferred revenue3,6953,051
Operating lease liabilities, current portion14,09913,031
Total current liabilities89,41389,096
Debt, noncurrent portion34,94234,935
Other noncurrent liabilities1,0121,307
Operating lease liabilities, noncurrent portion80,24283,072
Total liabilities205,609208,410
Commitments and contingencies (Note 8)
Stockholders’ equity:  
Preferred stock, $0.001 par value - 5,000 shares authorized; none issued and outstanding at June 30, 2023 and December 31, 202200
Common stock, $0.001 par value - 100,000 shares authorized; 30,550 shares at June 30, 2023 and 30,193 at December 31, 2022 issued and outstanding3028
Additional paid-in capital803,792762,380
Accumulated other comprehensive loss(152)(396)
Accumulated deficit(579,791)(522,200)
Total stockholders’ equity223,879239,812
Total liabilities and stockholders’ equity$ 429,488$ 448,222
Quentin S. Blackford
1700
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.